![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ALNYLAM GRANTS QIAGEN LICENSE TO KREUTZER-LIMMER PATENTS IN THE RESEARCH PRODUCTS MARKET
ALNYLAM GRANTS QIAGEN LICENSE TO KREUTZER-LIMMER PATENTS IN THE RESEARCH PRODUCTS MARKET
September 21, 2005
lnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has granted QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA), a leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins, a non-exclusive license to provide research products and services in RNA interference (RNAi) under the Kreutzer-Limmer patent family. This patent family, owned by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.
Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050921005182&newsLang=en)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct